Characterizing Developmental Trajectories and the Role of Neuropsychiatric Genetic Risk Variants in Early-Onset Depression

Frances Rice, PhD; Lucy Riglin, PhD; Ajay K. Thapar, PhD, MD; Jon Heron, PhD; Richard Anney, PhD; Michael C. O’Donovan, PhD, MD; Anita Thapar, PhD, MD

**IMPORTANCE** Depression often first manifests in adolescence. Thereafter, individual trajectories vary substantially, but it is not known what shapes depression trajectories in youth. Adult studies suggest that genetic risk for schizophrenia, a psychiatric disorder with a neurodevelopmental component, may contribute to an earlier onset of depression.

**OBJECTIVE** To test the hypothesis that there are distinct trajectories of depressive symptoms and that genetic liability for neurodevelopmental psychiatric disorders (eg, schizophrenia, attention deficit/hyperactivity disorder [ADHD]), as well as for major depressive disorder (MDD), contribute to early-onset depression.

**DESIGN, SETTING, AND PARTICIPANTS** The Avon Longitudinal Study of Parents and Children is an ongoing, prospective, longitudinal, population-based cohort that has been collecting data since September 6, 1990, including data on 7543 adolescents with depressive symptoms at multiple time points. The present study was conducted between November 10, 2017, and August 14, 2018.

**MAIN OUTCOMES AND MEASURES** Trajectories based on self-reported depressive symptoms dichotomized by the clinical cutpoint; MDD, schizophrenia, and ADHD polygenic risk score (PRS) were predictors.

**RESULTS** In 7543 adolescents with depression data on more than 1 assessment point between a mean (SD) age of 10.64 (0.25) years and 18.65 (0.49) years (3568 [47.3%] male; 3975 [52.7%] female), 3 trajectory classes were identified: persistently low (73.7%), later-adolescence onset (17.3%), and early-adolescence onset (9.0%). The later-adolescence-onset class was associated with MDD genetic risk only (MDD PRS: odds ratio [OR], 1.27; 95% CI, 1.09-1.48; \( P = .003 \)). The early-adolescence-onset class was also associated with MDD genetic risk (MDD PRS: OR, 1.24; 95% CI, 1.06-1.46; \( P = .007 \)) but additionally with genetic risk for neurodevelopmental disorders (schizophrenia PRS: OR, 1.22; 95% CI, 1.04-1.43; \( P = .01 \); ADHD PRS: OR, 1.32; 95% CI, 1.13-1.54; \( P < .001 \)) and childhood ADHD (\( \chi^2 = 6.837; P = .009 \)) and neurodevelopmental traits (pragmatic language difficulties: OR, 1.31; \( P = .004 \); social communication difficulties: OR, 0.68; \( P < .001 \)).

**CONCLUSIONS AND RELEVANCE** The findings of this study appear to demonstrate evidence of distinct depressive trajectories, primarily distinguished by age at onset. The more typical depression trajectory with onset of clinically significant symptoms at age 16 years was associated with MDD genetic risk. The less-common depression trajectory, with a very early onset, was particularly associated with ADHD and schizophrenia genetic risk and, phenotypically, with childhood ADHD and neurodevelopmental traits. Findings are consistent with emerging evidence for a neurodevelopmental component in some cases of depression and suggest that the presence of this component may be more likely when the onset of depression is very early.

Published online October 14, 2018.
Major depressive disorder (MDD) is the most common mental disorder and a leading cause of disability; even subthreshold depressive symptoms are associated with functional impairment and future mental health problems.1,2 Depression often first manifests in adolescence and, thereafter, individual trajectories of depressive symptoms vary substantially.3 A family history of depression and an early age at onset are each associated with a more chronic symptom course in adults with MDD.3-6 but it is not known what shapes early depression trajectories in youth.

Depression has a complex multifactorial set of causes, including a moderate heritable component.4,11,12 Longitudinal and family studies show continuity between both adolescence-onset depressive disorder and symptoms with depression in adult life, but there are also developmental differences between depression in children, adolescents, and adults.4 For instance, clinical follow-up studies of very early-onset depression (average age at onset, 10.7 years) report high rates of heterotypic continuity, where depression is often followed by a different type of clinical disorder.13-15 Twin studies also show differences in the genetic set of causes of very early-onset depressive symptoms compared with those arising in mid- to late adolescence.16-18

At the molecular level, a recent genome-wide association study of adults with MDD found evidence of differences in the genetic architecture of depression where a relatively early age at onset (before the median age at onset of 27 years) was associated with genetic liability to schizophrenia, an association not seen for later-onset depression, which was instead associated with MDD risk alleles.19 Similar findings have been reported for emotional problems (symptoms of depression and anxiety) in that emotional problems in childhood were associated with schizophrenia risk alleles, but in adult life they were additionally associated with MDD genetic risk.20 The association of schizophrenia risk alleles with childhood emotional problems was particularly pronounced in those with emotional problems in both childhood and adulthood, suggesting that persistent emotional symptoms beginning early may drive the association with schizophrenia risk alleles. As schizophrenia genetic risk is thought to involve an early neurodevelopmental component,21-23 the role of genetic risk for other neurodevelopmental disorders in early-onset depression may be important to consider. In particular, genetic risk for ADHD, a common childhood-onset neurodevelopmental disorder, may be important in early-onset depression because cross-sectional and longitudinal cohort studies show heightened rates of depression in children with ADHD,23-25 which may be partly due to the strong genetic correlation between ADHD and depression ($r_g = 0.424$).26,27

Herein, we test the contribution of neuropsychiatric disorder genetic risk variants, specifically genetic liability to MDD, schizophrenia, and ADHD, to early depression trajectories. Schizophrenia and ADHD were selected in addition to MDD as they show moderate to high genetic correlations with major depression,28 there is evidence linking schizophrenia polygenic risk score (PRS) to early-onset depression,19,20 and epidemiologic and clinical evidence15,23-25 that ADHD may be an important antecedent of depression.
Depressive symptoms were reported by the young person at 6 time points (ages 10.5, 12.5, 13.5, 16.5, 17.5, and 18.5 years) on the short Mood and Feelings Questionnaire. This is a well-validated symptom checklist \(^{34-36}\) that includes 13 items about mood symptoms during the past 2 weeks (rated 0, not true; 1, sometimes true; or 2, true; score range, 0-26). Scores above 11 represent clinically significant symptoms.\(^{34,36}\)

Polygenic risk scores for MDD, schizophrenia, and ADHD were generated in study individuals as the standardized mean number of disorder risk alleles in approximate linkage equilibrium (\(R^2 \leq 0.20\)), weighted by genome-wide association study allele effect size derived from data of imputed autosomal single-nucleotide polymorphisms. All analyses were performed using Stata, version 13.0 (StataCorp) to implement the PLINK toolset (http://zzz.bwh.harvard.edu/plink/; code is available at https://github.com/ricanney/stata). In brief, best-guess genotype underwent additional marker and individual quality control. Individuals were excluded on the basis of excessive heterozygosity (>4 SDs from sample mean), relatedness (>3 SDs from sample mean), and genotype missingness (>2%). Markers were excluded if they were rare (minor allele count <5), had high levels of missingness (>2%), or deviated from Hardy-Weinberg equilibrium (\(P \leq 10^{-10}\)) or from reference minor allele frequency (>10%) (eMethods in the Supplement).

Scores were derived from MDD, ADHD, and schizophrenia weights for 152 536, 103 041, and 27 336 single-nucleotide polymorphisms, respectively. Risk alleles were defined as those associated with case status in the most recent Psychiatric Genomics Consortium analyses of MDD, ADHD, and schizophrenia at a threshold of \(P < .50\) for depression and ADHD and \(P < .05\) for schizophrenia, as these thresholds maximally capture phenotypic variance.\(^{26-29,37}\) Genome-wide association study discovery sample sizes were 130 664 cases and 330 470 controls for MDD, 20 183 cases and 35 191 controls for ADHD, and 35 476 cases and 46 839 controls for schizophrenia. All PRSs were standardized prior to analysis so odds ratios (ORs) represent 1 SD change (eTable 2A in the Supplement). Phenotypic measures of neurodevelopmental problems (DSM-IV\(^{38}\) diagnoses of childhood ADHD, social communication problems, and pragmatic language difficulties at age 7 years), psychotic experiences (ages 12 and 17 years), family history of severe depression and schizophrenia, and maternal educational level were used (eMethods in the Supplement).

**Statistical Analysis**

We characterized depression trajectories of symptoms dichotomized by clinical cutoff (n = 7543) using latent class growth analysis in Mplus, version 8.\(^{39}\) This analysis is a probability-based technique used to identify an optimum number of distinct patterns (classes) of growth (change) in the longitudinal depression scores of individuals.\(^{40}\) Models were run with increasing numbers of classes, starting with a 1-class solution specifying both linear and quadratic change with 500 random starting values and 50 optimizations. Residual variances were allowed to vary across measurement points. A maximum likelihood parameter estimator for which SEs are robust to nonnormality was used.

To examine associations with categorical variables (eg, sex), the DCAT auxiliary option in Mplus was used. A bias-free, 3-step approach in MPlus (RSTEP) estimated the associations between continuous hypothesized predictor variables (PRSs) and trajectory class.\(^{41-43}\) Model selection was informed by model fit indices and interpretability as recommended.\(^{44}\) Full information maximum likelihood estimation was used in MPlus and included all individuals with more than 1 depression assessment in analyses (eTable 1 in the Supplement). For tests of PRS association with trajectory class, we reran analyses using inverse probability weighting\(^{45}\) to address any potential bias caused by participant dropout. The pattern of results was similar (eTable 3 in the Supplement).
Results

Depression Symptom Trajectories

A 3-class trajectory model provided the best fit to the data and results that were most readily interpretable (eTable 1 and eAppendix 1 in the Supplement). The Figure shows the 3 distinct trajectory classes: a persistently low class (73.7%), a later-adolescence–onset class (17.3%), and an early-adolescence–onset class (9.0%). In the early-adolescence–onset class, the probability of clinically significant depression was first elevated (as indicated by a probability of clinically significant depression symptomatology of 0.44) at age 12.5 years, which rose to 0.52 at 13.5 years. In the later-adolescence–onset class, the probability of clinically significant depression (probability, 0.47) was first elevated at age 16.5 years and rose at 17.5 years (probability, 0.57). Both elevated trajectories were associated with a diagnosis of MDD (assessed by the Clinical Interview Schedule—Revised at age 17.5 years) providing validation of the trajectory classes (later-adolescence onset, 34.4%; early-adolescence onset, 22.8%; low level, 15%; overall difference, \( \chi^2 = 193.70; P = .000 \)). The estimated proportion of females was 45.8% in the low-level class and was higher, but did not differ significantly, between the early-adolescence– (74.3%) and later-adolescence– (73.2%) onset classes (Table 1).

Neuropsychiatric PRS and Trajectory Class

As reported in Table 2, the later-adolescence–onset class was associated only with higher MDD PRS (OR, 1.27; 95% CI, 1.09-1.48; \( P = .003 \)). The early-adolescence–onset class was associated with higher PRSs for ADHD (OR, 1.32; 95% CI, 1.13-1.54; \( P < .001 \)), schizophrenia (OR, 1.22; 95% CI, 1.04-1.43; \( P = .01 \)), and MDD (OR, 1.24; 95% CI, 1.06-1.46; \( P = .007 \)). Post hoc, we examined the association with all 3 psychiatric PRSs and trajectory class to examine which PRS contributed most strongly (Table 2). As expected, the PRSs were correlated (eTable 2B and C in the Supplement).

Multivariate analysis showed that the strongest association with the early-adolescence–onset class was observed for ADHD PRS, the association with schizophrenia PRS was retained, and the association with MDD PRS became nonsignificant (Table 2). Results for the later-adolescence–onset class remained the same. Comparing the early- and later-onset classes showed significant differences (MDD PRS: OR, 1.13; 95% CI, 0.88-1.46; \( P = .33 \); schizophrenia PRS: OR, 0.78; 95% CI, 0.60-

### Table 1. Phenotypic Associations With Trajectory Class

<table>
<thead>
<tr>
<th>Variable</th>
<th>Onset, OR (95% CI)</th>
<th>Early Adolescence</th>
<th>P Value</th>
<th>Later Adolescence</th>
<th>P Value</th>
<th>( \chi^2 ) or OR (95% CI)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex, %</td>
<td></td>
<td>74.3</td>
<td>&lt;.001</td>
<td>73.2</td>
<td>&lt;.001</td>
<td>( \chi^2 = 0.015 )</td>
<td>.90</td>
</tr>
<tr>
<td>Maternal education, completed A-levels, %c</td>
<td>39.1</td>
<td>.01</td>
<td>34.9</td>
<td>.001</td>
<td>( \chi^2 = 0.707 )</td>
<td>.44</td>
<td></td>
</tr>
<tr>
<td>Childhood ADHD, %</td>
<td>6.3</td>
<td>.008</td>
<td>0.9</td>
<td>.37</td>
<td>( \chi^2 = 6.837 )</td>
<td>.009</td>
<td></td>
</tr>
<tr>
<td>Pragmatic language difficultiesd</td>
<td>0.63 (0.55-0.71)</td>
<td>&lt;.001</td>
<td>0.82 (0.72-0.94)</td>
<td>.006</td>
<td>OR, 1.31</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Social communication difficultiese</td>
<td>1.50 (1.34-1.68)</td>
<td>&lt;.001</td>
<td>1.01 (0.87-1.18)</td>
<td>.86</td>
<td>OR, 0.68</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Psychotic experiences</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>( \chi^2 = 18.819 )</td>
<td>.001 (for Cutoff)</td>
</tr>
<tr>
<td>12 y</td>
<td>1.47 (1.35-1.61)</td>
<td>&lt;.001</td>
<td>0.89 (0.64-1.22)</td>
<td>.46</td>
<td>OR, 0.60</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17 y</td>
<td>1.57 (1.36-1.80)</td>
<td>&lt;.001</td>
<td>1.54 (1.33-1.79)</td>
<td>&lt;.001</td>
<td>OR, 0.99</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviations:** ADHD, attention deficit/hyperactivity disorder; OR, odds ratio.  
* Continuous scores are standardized so that ORs are for 1-SD increase. Low-risk group was the reference group except for tests of comparison between early-adolescence- and later-adolescence-onset groups where the early-adolescence-onset group was the reference group.  
** χ² Tests of difference for social communication and pragmatic language difficulties used the established clinical cut-points for identifying problems (eAppendix in the Supplement). The OR values represent the difference between the ORs in the preceding columns for later-adolescence onset vs early-adolescence onset.  
* A-level education is equivalent to high school diploma in the United States  
** Lower scores represent more difficulties.  
* Higher scores represent more problems.

### Table 2. Associations of Polygenic Risk Scores With Trajectory Classes

<table>
<thead>
<tr>
<th>Association</th>
<th>Onset, OR (95% CI)</th>
<th>Early Adolescence</th>
<th>P Value</th>
<th>Later Adolescence</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Univariate</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MDD PRS</td>
<td>1.24 (1.06-1.46)</td>
<td>.007</td>
<td>1.27 (1.09-1.48)</td>
<td>.003</td>
<td></td>
</tr>
<tr>
<td>Schizophrenia PRS</td>
<td>1.22 (1.04-1.43)</td>
<td>.01</td>
<td>.95 (0.82-1.11)</td>
<td>.56</td>
<td></td>
</tr>
<tr>
<td>ADHD PRS</td>
<td>1.32 (1.13-1.54)</td>
<td>&lt;.001</td>
<td>.94 (0.80-1.11)</td>
<td>.48</td>
<td></td>
</tr>
<tr>
<td>Multivariate</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MDD PRS</td>
<td>1.16 (0.98-1.36)</td>
<td>.09</td>
<td>1.31 (1.12-1.53)</td>
<td>.001</td>
<td></td>
</tr>
<tr>
<td>Schizophrenia PRS</td>
<td>1.19 (1.01-1.41)</td>
<td>.04</td>
<td>.93 (0.79-1.10)</td>
<td>.39</td>
<td></td>
</tr>
<tr>
<td>ADHD PRS</td>
<td>1.27 (1.08-1.50)</td>
<td>.003</td>
<td>.90 (0.76-1.07)</td>
<td>.23</td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviations:** ADHD, attention deficit/hyperactivity disorder; MDD, major depressive disorder; OR, odds ratio; PRS, polygenic risk score.
relatively earlier onset is more strongly associated with schizophrenia polygenic risk.\textsuperscript{19,20,52} We found an additional contribution from ADHD PRSs.

The implication of those results is that early- and later-adolescence-onset depression differ to some extent with respect to the risk factors involved and that the earlier-onset disorder is more strongly influenced by neurodevelopmental factors than depression with a more typical onset in later adolescence or early adulthood. This finding is consistent with a number of observations from epidemiologic, family, and clinical studies. First, several family and clinical follow-up studies suggest that childhood-onset depression might differ etiologically from adolescent-onset depression.\textsuperscript{53-56} Second, the epidemiologic factors associated with very early-onset depression differ from those of depression with onset in midadolescence to late adolescence in the sex ratio of affected individuals and long-term psychiatric outcomes.\textsuperscript{15,57} Third, neurodevelopmental difficulties, including speech abnormalities and poor motor skills, are particularly associated with early-onset rather than adolescent- or adult-onset depression.\textsuperscript{15,58,59} Fourth, substantial clinical evidence shows that children with ADHD, a common neurodevelopmental disorder, are at elevated risk of subsequent depressive symptoms, suicide attempt, and emotional problems in adult life.\textsuperscript{55,60-63}


**Discussion**

This study identified variation in the developmental trajectories of depression from childhood to early adult life, and moreover, that this variation is partly attributable to MDD, schizophrenia, and ADHD risk alleles. We found evidence of distinct depressive trajectories primarily distinguished by age at onset. We found that the more common, typical developmental trajectory, with onset after puberty and persistence into early adulthood,\textsuperscript{6,53} was associated with elevated genetic risk for depression indexed by MDD PRS. In contrast, we found that depressive symptoms defined by a very early onset (by age 12 years) were associated with all neuropsychiatric genetic risk scores assessed, with multivariate analysis showing that the association was strongest for ADHD PRS.

Phenotypically, childhood neurodevelopmental difficulties (ADHD, pragmatic language, and social communication difficulties) differentiated the depression trajectories that were elevated only in the early-adolescence–onset group with rates increased by 5- to 7-fold in the early-adolescence–onset group. Psychotic experiences differentiated the groups only at age 12 years. This discrepancy may be driven by depressive symptom differences between the groups at age 12 years (Figure) given the reported association between psychotic experiences and depression and an inconsistent association with psychotic experiences and schizophrenia PRS.\textsuperscript{45,50} The findings are consistent with a growing body of literature showing that depression has heterogeneous causes partly indexed by age at onset. In particular, studies of adult MDD and symptoms measured continuously in population-based samples illustrate that a relatively earlier onset is more strongly associated with schizophrenia polygenic risk.\textsuperscript{19,20,52} We found an additional contribution from ADHD PRSs.
Developmental Trajectories and Neuropsychiatric Genetic Risk Variants in Early-Onset Depression

Supervision: A.K. Thapar, Anney, O'Donovan.

Administrative, technical, or material support: Obtained funding: Rice, A. Thapar.

Critical revision of the manuscript for important accuracy of the data analysis: Rice, A. Thapar.

Role of the Funder/Sponsor: This study was supported by grant MR/R004609/1 from the Medical Research Council (Dr Rice) and Wellcome grant 102219/Z/13/Z and the University of Bristol provide core support for Avon Longitudinal Study of Parents and Children (ALSPAC).

Role of the Funder/Sponsor: The UK Medical Research Council and Wellcome grant 102219/Z/13/Z and the University of Bristol provide core support for Avon Longitudinal Study of Parents and Children (ALSPAC).

Conflict of Interest Disclosures: None.

Funding/Support: This study was supported by grant MR/R004609/1 from the Medical Research Council (Dr Rice, A. K. Thapar, Heron, and A. Thapar) and by a seed corn grant from the MRC Centre for Neuropsychiatric Genetics and Genomics (Dr Rice). The UK Medical Research Council and Wellcome grant 102219/Z/13/Z and the University of Bristol provide core support for Avon Longitudinal Study of Parents and Children (ALSPAC).

Conflict of Interest Disclosures: None.

Funding/Support: This study was supported by grant MR/R004609/1 from the Medical Research Council (Dr Rice, A. K. Thapar, Heron, and A. Thapar) and by a seed corn grant from the MRC Centre for Neuropsychiatric Genetics and Genomics (Dr Rice). The UK Medical Research Council and Wellcome grant 102219/Z/13/Z and the University of Bristol provide core support for Avon Longitudinal Study of Parents and Children (ALSPAC).

Strengths and Limitations

Strengths of this study include the repeated-measures longitudinal design where depression was assessed using the same measure and informant. Typically, longitudinal studies include changes in measurement and informant, in particular, as children age, the informant tends to change from the parent to the young person. This variation provides a challenge to studies seeking to examine the development of symptoms over time because changes of measurement and informant can affect results. This invariance of measurement over time is a strength.

One limitation of our investigation is that, like many longitudinal studies, nonrandom attrition occurs in ALSPAC over time (eAppendix 2 in the Supplement). This nonrandom loss of participants is likely to result in conservative estimates of the prevalence of the elevated depression trajectory groups. We used a number of approaches to deal with missing data, including full information maximum likelihood in trajectory modeling and inverse probability weighting for tests of association. The pattern of results was replicated using inverse probability weighting. Nonetheless, the missing data assumption made in our analyses is that there are not systematic differences between participants who do and do not provide trajectory data and membership in the sample after conditioning on the other variables in the model (eg, PRS and variables included in the inverse probability weighting analysis).

Depression was assessed using self-reported questionnaires rather than clinical assessment. Nonetheless, subthreshold symptoms are associated with impairment and subsequent MDD. It was not possible to investigate rates of mania or bipolar disorder in the trajectory groups. However, evidence is inconsistent on the link with early-onset depression and bipolar disorder. The follow-up period in this study was limited to early adult life. A final limitation is that PRSs are weak predictors and explain only a small to modest proportion of phenotypic variance as they do in the present article. However, they provide a useful biological indicator of genetic liability.

Conclusions

The findings of this study suggest etiologically distinct trajectories of depressive symptoms in youth dependent on age at onset. The findings also show that neurodevelopmental genetic risk contributes to very early-onset depression.

REFERENCES


